ArticleThe Journal of clinical investigation2021
Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicle-mediated trafficking.
Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 55 citations in OpenAlex.
- Antifungal turbinmicin alters functional vesicle cargo.Antimicrobial agents and chemotherapy · 2026Article
- Current and emerging therapies for fungal biofilms and systemic infections.Critical reviews in microbiology · 2026Review
- The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release.PLoS pathogens · 2025Article
- A brief history of phosphatidylinositol transfer proteins: from the backwaters of cell biology to prime time in lipid signaling.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2025Review
- Vesicle inhibition reducesAntimicrobial agents and chemotherapy · 2025Article
- Things you wanted to know about fungal extracellular vesicles (but were afraid to ask).PLoS neglected tropical diseases · 2025Article
- Extracellular vesicles from bacteria and fungi: mechanistic insights and implications for urinary tract infections.Extracellular vesicles and circulating nucleic acids · 2025Review
- Review
- Host immune response against fungal biofilms.Current opinion in microbiology · 2024Review
- Genome-Guided Identification of Surfactin-ProducingInternational journal of molecular sciences · 2024Article
- The progress and future of the treatment of Candida albicans infections based on nanotechnology.Journal of nanobiotechnology · 2024Review
- Diagnostic and Therapeutic Challenge Caused byPathogens (Basel, Switzerland) · 2024Review
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
- Fangchinoline inhibits growth and biofilm of Candida albicans by inducing ROS overproduction.Journal of cellular and molecular medicine · 2024Article
- Microbial extracellular vesicles contribute to antimicrobial resistance.PLoS pathogens · 2024Review
- Marine-Derived Metabolites Act as Promising Antifungal Agents.Marine drugs · 2024Review
- Article
- The role of theCell surface (Amsterdam, Netherlands) · 2023Review
- Antifungal therapy ofBiofilm · 2023Article
- Traversing the Cell Wall: The Chitinolytic Activity ofJournal of fungi (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The emergence of drug-resistant fungi has prompted an urgent threat alert from the US Centers for Disease Control (CDC). Biofilm assembly by these pathogens further impairs effective therapy. We recently identified an antifungal, turbinmicin, that inhibits the fungal vesicle-mediated trafficking pathway and demonstrates broad-spectrum activity against planktonically growing fungi. During biofilm growth, vesicles with unique features play a critical role in the delivery of biofilm extracellular matrix components. As these components are largely responsible for the drug resistance associated with biofilm growth, we explored the utility of turbinmicin in the biofilm setting. We found that turbinmicin disrupted extracellular vesicle (EV) delivery during biofilm growth and that this impaired the subsequent assembly of the biofilm matrix. We demonstrated that elimination of the extracellular matrix rendered the drug-resistant biofilm communities susceptible to fungal killing by turbinmicin. Furthermore, the addition of turbinmicin to otherwise ineffective antifungal therapy potentiated the activity of these drugs. The underlying role of vesicles explains this dramatic activity and was supported by phenotype reversal with the addition of exogenous biofilm EVs. This striking capacity to cripple biofilm assembly mechanisms reveals a new approach to eradicating biofilms and sheds light on turbinmicin as a promising anti-biofilm drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.